Clobetasol Propionate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Clobetasol Propionate
- Clobetasol Propionate: From Atopic Eczema and Contact Dermatitis to Vulvar Inverted Follicular Keratosis
Clobetasol Propionate: From Atopic Eczema and Contact Dermatitis to Vulvar Inverted Follicular Keratosis
One-Sentence Summary
Clobetasol propionate is a super-potent topical corticosteroid, originally used for inflammatory skin conditions such as atopic eczema, contact dermatitis and seborrheic dermatitis. The TxGNN model predicts it may be effective for vulvar inverted follicular keratosis, but there are currently 0 clinical trials and 0 publications supporting this specific prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Atopic eczema, contact dermatitis, seborrheic dermatitis and related inflammatory dermatoses (taken from the knowledge-graph indications, because the Singapore licence records carry no indication text) |
| Predicted New Indication | Vulvar inverted follicular keratosis |
| TxGNN Prediction Score | 99.46% |
| Evidence Level | L5 (model prediction only) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 13 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action text is not available for this report. The pharmacology data show that clobetasol propionate acts on the glucocorticoid receptor (NR3C1). Through this receptor, topical corticosteroids suppress inflammation, itching and cell proliferation in the skin, which is why clobetasol works in eczema and dermatitis.
The model likely links the new indication to seborrheic keratosis, one of the original indications. Inverted follicular keratosis is a benign epithelial lesion closely related to seborrheic keratosis. However, the link is weak mechanistically. Inverted follicular keratosis is a benign proliferation of keratinocytes, not an inflammatory disease, so an anti-inflammatory steroid has no clear reason to treat it. No trials or publications support topical clobetasol for the vulvar form. The high score therefore reflects similarity in the knowledge graph rather than demonstrated benefit.
Other predictions with more support (for context):
- Psoriasis (score 96.3%) has the strongest evidence, with many Phase 3 and Phase 4 trials and many reviews across spray, foam, shampoo, ointment and cream. However, psoriasis is already a labelled use of clobetasol products, so it is an established indication, not new repurposing.
- Exanthem (score 99.3%) is supported mostly by trials in oral lichen planus, including one completed Phase 3 trial in vulvar lichen sclerosus. These do not directly cover exanthem.
- Acne keloidalis (score 99.2%) has one small open-label study (20 patients, 2005) of clobetasol foam. This is limited but directly relevant.
Clinical Trial Evidence
Currently no related clinical trials registered for vulvar inverted follicular keratosis.
Literature Evidence
Currently no related literature available for vulvar inverted follicular keratosis.
Singapore Market Information
There are 13 valid single-ingredient registrations and no cancelled ones. The licence records contain no approved-indication text. The main authorizations are listed below.
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN13239P | Clobex Shampoo 0.05% | Shampoo |
| SIN04933P | Dermovate Ointment 0.05% w/w | Ointment |
| SIN04934P | Dermovate Cream 0.05% w/w | Cream |
| SIN04499P | Dermovate Scalp Application 0.05% w/w | Lotion |
| SIN07548P | Univate Cream 0.05% w/w | Cream |
Other registered products include Medodermone (ointment and cream), Tempovate, Steriderm-S, Lobesol, Univate ointment, Clonovate and Dermosol. Topical dosage forms are therefore already available in Singapore.
Safety Considerations
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for full safety information.
Contraindication signals from the knowledge graph (not label text): hyperglycaemia, diabetes mellitus, diabetic ketoacidosis, adrenocortical insufficiency, Addison disease, glaucoma, skin atrophy, folliculitis, seborrheic dermatitis, and peripheral vascular or arterial disease (including intermittent claudication).
Trial data from other indications point to two class concerns for a super-potent steroid. One is suppression of the adrenal (HPA) axis with prolonged or wide-area use, including in children. The other is skin atrophy, which matters on thin vulvar skin.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (L5). It has no clinical trials or literature, and the mechanism is not convincing for a benign keratinocytic proliferation. The vulvar site also raises the risk of atrophy and systemic absorption with a super-potent steroid.
To proceed, the following is needed:
- Case series or clinical studies of topical clobetasol in biopsy-confirmed inverted follicular keratosis, or an expert dermatology and gynaecology review of whether treatment is warranted at all, since the lesion is benign
- Package insert warnings and contraindications from the HSA records
- Detailed mechanism-of-action data
- Safety limits for vulvar use, such as duration, area and HPA-axis monitoring
- Consideration of redirecting effort to better-supported candidates, such as acne keloidalis, where a small open-label study exists
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.